Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

• Industry analysts project that REEs used in clean-energy technologies could see demand increase two to three times by 2040.
• Despite the importance of these precious elements, global supply chains for REEs remain highly concentrated.
• Ucore is developing technologies and facilities designed to process rare earth concentrates into high-purity oxides that can be used in manufacturing.

Rare earth elements have become one of the most strategically important groups of materials in the modern global economy, underpinning technologies that range from electric vehicles to advanced defense systems. As demand accelerates and supply remains heavily concentrated overseas, Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is working to establish itself as a key participant in building a secure North American rare earth supply chain through its focus on processing and separation technologies.

Rare earth elements (“REEs”) are a group of essential metals that possess unique magnetic, luminescent and electrochemical properties, making them essential for a wide range of high-tech applications. According to the U.S. Geological Survey, these materials are critical inputs in permanent magnets, catalysts, phosphors and advanced alloys used in electronics, renewable energy systems and defense technologies. Among the most commercially important are neodymium, praseodymium, dysprosium, terbium, samarium and gadolinium, which are used to manufacture high-performance magnets that power electric motors, wind turbine generators and precision-guided military equipment.

Demand for these materials continues to grow rapidly. Industry analysts project that REEs used in clean-energy technologies could see demand increase two to three times by 2040 under current policy scenarios, driven by the expansion of electric vehicles, wind energy and electrification across multiple industries. Electric vehicles rely on rare earth magnets to improve motor efficiency, while offshore wind turbines can require hundreds of kilograms of rare earth materials per installation. In the defense sector, the importance is equally significant. The U.S. Congressional Research Service has stated that a single F-35 fighter jet requires approximately 920 pounds of rare earth materials, highlighting their central role in national security systems.

Despite the importance of these precious elements, global supply chains for REEs remain highly concentrated. China dominates the production and processing of rare earth elements, accounting for a significant share of global output and maintaining substantial control over refining capacity. This concentration creates a structural vulnerability for countries that rely on imports for processed materials. 

In recent years, the United States has imported approximately 74% of its rare earth compounds and metals from China, underscoring the degree of dependency. Because the most technically complex part of the supply chain is the separation of rare earth oxides, even domestically mined materials often must be sent abroad for processing.

This imbalance has prompted growing concern among policymakers and industry leaders. The U.S. Department of Energy (“DOE”) has identified REEs as critical to both economic and national security, noting that supply chain disruptions could impact everything from clean-energy deployment to defense readiness. As geopolitical tensions and trade restrictions continue to influence global markets, the need for domestic and allied production capabilities has become more urgent. Strengthening domestic processing infrastructure is widely viewed as a key step in reducing reliance on foreign sources and ensuring long-term supply stability.

Efforts to build a domestic rare earth supply chain are increasingly focused on the midstream segment, particularly separation and refining. This is where Ucore Rare Metals is concentrating its efforts. Rather than focusing solely on mining, Ucore is developing technologies and facilities designed to process rare earth concentrates into high-purity oxides that can be used in manufacturing. The company’s proprietary RapidSX(TM) technology is intended to improve upon conventional solvent extraction methods by increasing efficiency, reducing processing time and lowering the physical footprint required for separation facilities.

Ucore has been advancing its Commercialization and Demonstration Facility in Kingston, Ontario, where it has conducted extensive testing of RapidSX under simulated commercial conditions. The data generated from this facility is being used to support the development of the company’s Strategic Metals Complex in Alexandria, Louisiana, where Ucore plans to deploy commercial-scale processing capacity for both light and heavy rare earth elements. The Louisiana facility is expected to play a central role in establishing a domestic supply of separated rare earth oxides in the United States.

The company’s strategy also includes building partnerships across the supply chain. Ucore has announced collaborations with magnet manufacturers and other industry participants aimed at integrating its processing capabilities with downstream production. These efforts are designed to support the creation of a complete mine-to-magnet supply chain within North America, reducing reliance on overseas processing and strengthening supply chain resilience.

In addition to its U.S. operations, Ucore is pursuing opportunities in Canada to expand its processing capabilities, including projects focused on samarium and gadolinium, two elements that are critical for high-temperature magnet applications and other advanced technologies. These initiatives are supported by government programs aimed at strengthening critical mineral supply chains, reflecting broader policy alignment with the company’s objectives.

As global demand for rare earth elements continues to rise and supply remains concentrated in a limited number of regions, the importance of developing domestic processing capacity is becoming increasingly clear. Ucore Rare Metals is positioning itself within this landscape by focusing on the technological and infrastructure challenges that define the rare earth supply chain. By advancing its RapidSX technology and building commercial processing facilities in North America, the company aims to play a meaningful role in strengthening supply security and supporting the industries that depend on these essential materials.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

• The organic agriculture sector continues to expand, creating demand for certified inputs that conventional chemical fertilizers cannot provide.
• Organic Phosphate is developing its Murdock Mountain project in northeastern Nevada to supply organic rock phosphate fertilizer to U.S. farmers, centered on direct-ship rock phosphate that requires minimal processing beyond grinding and bagging.
• Early drilling at the Murdock Mountain target zone has confirmed phosphate grades and low heavy-metal concentrations compatible with organic farming requirements, and the company has identified multiple phosphate target zones that could significantly expand the project’s overall scale.
• Infrastructure access, including nearby rail transport, may support distribution to agricultural regions across the United States.

As demand for organic food continues to grow across North America, attention is increasingly turning to the upstream inputs required to sustain that expansion. One of the most difficult inputs to scale has been phosphate fertilizer that complies with organic certification standards. Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, is positioning its Murdock Mountain project in northeastern Nevada as a potential supply solution for the organic agriculture sector. The company is exploring a phosphate-bearing formation at its Murdock Mountain property in Elko County with the objective of producing natural rock phosphate suitable for direct application on farmland.

Phosphate is one of the three primary nutrients essential to plant growth. In conventional agriculture, most phosphate fertilizers are produced through chemical processing of mined rock into products such as monoammonium phosphate or diammonium phosphate. While effective for crop production, these products generally do not qualify for use in certified organic farming systems. Organic growers therefore rely on a narrower range of phosphate inputs, often derived from livestock by-products such as bone meal or manure. Because those materials are linked to animal agriculture, supply has historically been difficult to expand at the pace required by rising consumer demand for organic foods.

Nevada Organic Phosphate’s strategy differs from the conventional fertilizer model. Rather than chemically processing phosphate rock, the company aims to mine naturally occurring rock phosphate that can be crushed, ground and shipped directly to agricultural users. This approach relies on the properties of reactive phosphate rock, which releases nutrients gradually as soil microorganisms interact with the mineral. The material is designed for direct application on fields, aligning with regenerative agricultural practices that emphasize soil biology and reduced chemical inputs.

The demand for phosphate fertilizer that complies with organic certification standards continues to grow. The North American organic food sector is estimated at roughly $35 billion annually, according to industry data referenced by the company, creating pressure to develop scalable fertilizer inputs that meet certification standards.

The company is focused on a phosphate target zone at its Murdock Mountain project. Early drilling has confirmed phosphate grades within the formation, along with relatively low concentrations of heavy metals that can present challenges for organic certification. According to company disclosures, the Murdock project has an exploration target ranging from approximately 10 million to 46 million tonnes of rock phosphate grading between roughly 3% and 15% P₂O₅. The estimate is conceptual in nature and based on early exploration data, including drilling and geological interpretation.

Additional target areas identified on the property could significantly expand the project’s overall scale. Nevada Organic Phosphate has reported that the broader Murdock Mountain area may host multiple phosphate zones that collectively could reach 200 million tonnes of phosphate-bearing material, pending further exploration. The geological formation extends for several kilometers around the Murdock Mountain area. Management plans additional drilling programs to better define the continuity of the phosphate layers and evaluate their suitability for future development.

Infrastructure access may also play a role in the project’s economics. The property is located in northeastern Nevada near Union Pacific rail lines, which could facilitate transport of fertilizer products to farming regions throughout the United States.

For organic agriculture, the quality profile of phosphate rock can be as important as its phosphorus content. Many global phosphate formations contain elevated levels of contaminants such as cadmium or other heavy metals, requiring chemical processing before use. Nevada Organic Phosphate has reported that assays from its drilling program show contaminant levels below thresholds typically associated with agricultural restrictions. The company believes this characteristic may allow the rock phosphate to be applied directly to farmland without the additional processing required for many conventional deposits.

Another aspect of the company’s model is the relative simplicity of production. Traditional phosphate fertilizer operations often involve large beneficiation and chemical processing facilities that require significant capital investment. By contrast, Nevada Organic Phosphate’s concept involves mining the rock, crushing and grinding it, then bagging and shipping the product to farmers. The company describes the process in straightforward operational terms: extract the rock, reduce it to a usable size, and distribute it to agricultural markets.

This approach could reduce capital intensity compared with conventional phosphate fertilizer production, while also limiting the environmental footprint associated with chemical processing.

The broader agricultural context may also favor the development of reactive phosphate sources. Some farming practices are gradually shifting toward direct application of mineral nutrients rather than highly soluble chemical fertilizers, particularly within regenerative and organic systems. Nevada Organic Phosphate believes this trend could create a distinct market segment separate from the traditional chemical fertilizer industry. Management has stated that the company does not expect to compete directly with large chemical fertilizer producers but instead aims to serve growers seeking organic-compliant inputs.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP

• Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings.
• Companies that consistently publish their findings often strengthen their credibility with both regulators and the medical community.
• Most recently, SNGX announced that a clinical summary of its HyBryte(TM) therapy for cutaneous T-cell lymphoma was published in the peer-reviewed journal “Expert Opinion on Investigational Drugs.”

The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM) therapy, reinforcing the importance of scientific transparency as the company advances treatments for rare diseases.

Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings. Peer review serves as a quality control mechanism that evaluates the validity, significance and originality of research before it is disseminated to the broader scientific community, helping to maintain high standards in biomedical science. This process is particularly important in drug development, where clinical data must be rigorously scrutinized before gaining acceptance among clinicians, regulators and investors.

In addition to validating research, publication also facilitates knowledge sharing and scientific progress. Peer-reviewed publications allow researchers to build upon existing findings, supporting cumulative advancements in medicine and improving patient care outcomes over time. For biopharmaceutical companies, publishing clinical data can therefore help position therapies within the broader scientific landscape while enabling collaboration and informed clinical decision-making.

“Transparency of clinical trial information . . . is essential to scientific advancement,” states the Commissioner of Food and Drugs, Robert M. Califf, M.D. “Making clinical trial information publicly available fulfills the commitment to volunteer research participants and also enhances public trust. Simply put: if a human experimental study is done and the existence of the study and the results are not publicly available, it is difficult to assert that obligation of the researchers to contribute to generalizable knowledge has been met.” 

Companies that consistently publish their findings often strengthen their credibility with both regulators and the medical community. Soligenix is one of those companies. Most recently, SNGX announced that a clinical summary of its HyBryte therapy (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”) was published in the peer-reviewed journal “Expert Opinion on Investigational Drugs.”

Titled “Topical Hypericin: A Promising Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma,” the article was written by Brian Poligone, MD, PhD, the founder and medical director of the Rochester Skin Lymphoma Medical Group; Poligone is also the director of cancer biology research for the Rochester General Hospital Research Institute. Poligone and his team have participated in four HyBryte clinical studies and have gained extensive clinical experience and understanding of the HyBryte therapy. The publication provides an overview of the therapy’s mechanism of action, clinical development and potential role in treating CTCL, a rare form of non-Hodgkin lymphoma that primarily affects the skin.

CTCL is a chronic condition that can significantly impact quality of life, often presenting with persistent skin lesions, itching and inflammation. CTCL is typically slow growing but requires ongoing management, with treatment strategies often focused on controlling symptoms and delaying disease progression. This underscores the need for therapies that are both effective and well tolerated over long periods.

HyBryte is designed as a photodynamic therapy that combines synthetic hypericin, a photosensitizing agent, with visible light activation. Once applied to affected areas, the compound is activated by specific wavelengths of light, producing a localized therapeutic effect that targets malignant T-cells while minimizing damage to surrounding healthy tissue. Soligenix has reported that this approach may offer a non-systemic treatment option, which is particularly relevant in early-stage CTCL where patients often seek therapies with fewer systemic side effects.

The published clinical summary highlights data generated from HyBryte’s clinical development program, including prior late-stage trials evaluating its safety and efficacy profile. By consolidating these findings into a peer-reviewed format, the publication provides clinicians and researchers with a comprehensive overview of the therapy’s potential, supporting further evaluation and discussion within the medical community.

Importantly, publication in a journal such as “Expert Opinion on Investigational Drugs” places HyBryte within a broader scientific dialogue focused on emerging therapies. Journals of this type are widely read by clinicians and researchers, helping to disseminate new findings and inform future research directions. This level of visibility can play a meaningful role in shaping how new therapies are perceived and ultimately adopted in clinical practice.

Beyond HyBryte, Soligenix continues to apply its broader platform-based approach to drug development across multiple therapeutic areas, including rare diseases and inflammatory conditions. The company’s focus on generating and publishing clinical data reflects an ongoing commitment to scientific rigor as it advances its pipeline.

As the healthcare industry increasingly emphasizes evidence-based medicine, the importance of peer-reviewed research continues to grow. Soligenix’s recent publication represents more than a dissemination of data; it signals progress in the validation of a potential new therapy for a difficult-to-treat disease. By contributing to the scientific literature, the company not only advances its own clinical programs but also supports the broader effort to improve treatment options for patients living with rare and chronic conditions.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

• Recent analysis underscores the vulnerability of specialized rare earth elements samarium and gadolinium.
• This elevated risk profile is largely driven by the dominance of a single country in rare earth production and processing as well as increasing demand for the elements.
• Ucore is working to accelerate the commercial development of its planned processing capabilities for these materials.

Securing reliable supplies of specialized rare earth elements is becoming increasingly important as demand rises across defense, energy and advanced manufacturing sectors. With this in mind, Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) recently announced that it is accelerating commercial planning for the production of samarium and gadolinium, two critical materials used in high-performance magnet applications and other advanced technologies.

The importance of this announcement is closely tied to rising demand and constrained supply for these specific rare earth elements. Samarium is a key component of samarium-cobalt magnets, which are valued for their ability to operate at high temperatures and maintain magnetic strength in demanding environments such as aerospace systems, defense technologies and certain energy applications. 

Gadolinium, meanwhile, is used in nuclear reactors, medical imaging technologies such as MRI contrast agents and emerging clean-energy applications. The U.S. Geological Survey has identified rare earth elements broadly as critical minerals due to their essential role in modern technologies and the high risk of supply disruption tied to concentrated production.

Recent analysis from the U.S. Geological Survey further underscores the vulnerability of these materials. In its 2025 draft critical minerals assessment, samarium ranked as the number one mineral at highest supply disruption risk, while gadolinium was also placed in the high-risk tier, reflecting both supply concentration and growing demand pressures. 

This elevated risk profile is largely driven by the dominance of a single country in rare earth production and processing. China remains the leading global producer and processor of rare earth elements, creating a bottleneck in the supply chain that affects availability of separated oxides required for magnet manufacturing and other advanced uses.

Demand growth is also accelerating. According to the International Energy Agency (“IEA”), demand for rare earth elements used in clean-energy technologies could increase by two to three times by 2040, driven by the expansion of electric vehicles, wind power and other electrification trends. While much of this growth is tied to neodymium-based magnets, samarium-cobalt magnets remain essential for applications where higher thermal stability is required, particularly in defense and aerospace systems. These overlapping demand drivers contribute to a tightening market for both samarium and gadolinium, increasing the need for new sources of supply outside of existing dominant producers.

Against this backdrop, Ucore’s recent announcement focuses on accelerating the commercial development of its planned processing capabilities for these materials. The company stated that it is advancing engineering and planning work to support the production of samarium and gadolinium oxides as part of its broader rare earth separation strategy. This effort is tied to Ucore’s planned facilities in North America, including its Strategic Metals Complex in Louisiana and its activities in Kingston, Ontario, where it has been operating a Commercialization and Demonstration Facility to validate its proprietary RapidSX(TM) technology.

RapidSX is central to Ucore’s approach. The technology is designed to improve upon conventional solvent extraction methods used to separate rare earth elements into individual oxides. According to the company, RapidSX aims to reduce processing time and plant footprint while maintaining or improving separation efficiency, enabling a more flexible and scalable approach to rare earth refining. This capability is particularly important for heavy and mid-range rare earth elements such as samarium and gadolinium, which require precise separation processes to achieve the purity levels needed for downstream applications.

Ucore’s broader strategy involves creating a North American supply chain for rare earth oxides that reduces reliance on overseas processing. The company has been working to align its processing plans with both upstream feedstock sources and downstream magnet manufacturing capacity. Previous announcements include a strategic alliance with Vacuumschmelze and eVAC Magnetics LLC to support the supply of rare earth oxides for permanent magnet production, linking Ucore’s refining capabilities to manufacturing operations in western markets.

In addition, Ucore has received conditional support from the government of Canada for its Canadian processing initiatives, including funding of up to C$36.3 million to advance a facility focused on refining samarium and gadolinium oxides. This support reflects broader policy efforts in North America to strengthen domestic critical mineral supply chains and ensure access to materials that are essential for both economic and national security.

The company’s latest announcement builds on these developments by emphasizing a more targeted focus on samarium and gadolinium as strategic materials within its portfolio. By accelerating commercial planning for these elements, Ucore is positioning itself to address a segment of the rare earth market that combines high demand, limited supply and strong geopolitical relevance. As global supply chains continue to evolve and demand for advanced materials increases, the ability to produce these specific oxides domestically may become an increasingly important differentiator.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• The company’s AI-driven digital asset trading platform combines artificial intelligence, blockchain settlement, and EU-compliant market infrastructure, and CEO Patrick Gruhn is expected to outline the company’s strategy and engage with investors at the Emerging Growth Conference, taking place online April 1, 2026.
• Perpetuals operates technology supporting a CySEC-authorized multilateral trading facility under European regulatory frameworks.

Perpetuals.com (NASDAQ: PDC), a fintech company developing AI-powered trading products and prediction markets, announced that CEO Patrick Gruhn will deliver a presentation and participate in a live question-and-answer session with investors at the Emerging Growth Conference on April 1 at 12:35 p.m. Eastern Time. The free, online event will provide an overview of the company’s AI-driven trading infrastructure and its broader strategy (https://ibn.fm/6FTub). According to details released by the company, investors will be able to watch the presentation via live webcast through the conference portal (https://EmergingGrowth.com).

Perpetuals’ platform has also been designed to comply with European regulatory regimes, including MiFID II, MiCA, DORA, and EMIR. The regulatory positioning reflects a broader structural shift within digital asset markets. While demand for leveraged crypto exposure continues to expand, many traditional brokers and financial institutions face regulatory barriers that limit their ability to connect with offshore trading venues.

Perpetuals aims to fill that gap by providing compliant infrastructure that brokers and institutions can access through application programming interfaces rather than building their own derivatives engines. Artificial intelligence is central to the company’s platform design. Perpetuals says its machine-learning models have been trained on data representing more than 11.7 billion order-book fills, covering over 22 billion trades. The data feeds algorithms intended to analyze liquidity conditions, trader behavior, and market risk in real time. The company believes such analytics could help address some of the structural weaknesses in crypto derivatives markets, particularly those related to sudden liquidation cascades and opaque pricing mechanisms.

Perpetuals recently introduced a derivatives contract known as Barrier Futures, which management says is designed to address concerns surrounding two dominant categories of leveraged trading: perpetual swaps and retail contracts for difference. Perpetual swaps, widely traded on offshore crypto exchanges, account for between $100 billion and $300 billion in daily volume. At the same time, the global CFD brokerage market includes roughly 19 million retail traders. Combined with broader over-the-counter derivatives activity, these segments represent markets with annual notional value measured in hundreds of trillions of dollars.

Barrier Futures attempts to differentiate itself structurally. Unlike perpetual swaps, the contract embeds mandatory knock-out barriers at the moment a position is opened. Those barriers define the maximum loss upfront. As a result, traders face no margin calls, no forced liquidations and no recurring funding payments.

The product is designed to operate within a regulated environment rather than relying on offshore venues. Perpetuals’ infrastructure supports a CySEC-authorized multilateral trading facility, allowing the contracts to be executed within a regulated European framework rather than through bilateral broker relationships typical of the CFD industry. Barrier Futures also allow brokers to compete with prediction markets by wrapping them into Barrier Future contracts.

For more information, visit the company’s website at www.Perpetuals.com.

NOTE TO INVESTORS: The latest news and updates relating to PDC are available in the company’s newsroom at https://ibn.fm/PDC

• Beeline Holdings Inc., in a recent update call, reported 127% year-over-year revenue growth for Q4 2025, reflecting the expansion of its digital mortgage platform.
• Mortgage origination volume rose 44% to $84.7 million during the quarter, and average revenue per loan increased 31%, while cost per loan declined 18%, indicating improving unit economics.
• Q4 also had the company releasing BeelineEquity, a blockchain-recorded platform allowing homeowners an efficient way to access equity without refinancing.
• Management says the company ended 2025 debt-free, strengthening its balance sheet ahead of expansion, and executives expect accelerating revenue growth in 2026 as new products and AI-driven automation scale.

Beeline Holdings (NASDAQ: BLNE),  a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, reported strong revenue growth and improving loan economics in its recently reported fourth-quarter 2025 results, highlighting a strategy that combines digital mortgage origination with new fee-based real-estate finance products. The fintech lender posted net revenue of $2.5 million in the fourth quarter, up 127% from the same period a year earlier and 8.3% sequentially. Mortgage originations reached $84.7 million, a 44% increase year over year (https://ibn.fm/DqJaW).

Management discussed the results during a March 30 conference call reviewing the company’s financial performance and outlook for 2026. Chief executive and co-founder Nick Liuzza said 2025 represented a transition year as the company strengthened its capital structure and completed key technology investments. “In 2025 we became a public company, strengthened the balance sheet through equity capital raises and the elimination of debt, and built our technology stack,” Liuzza said.

Beeline’s growth was supported by improving operational efficiency across its mortgage platform. According to chief operating officer and co-founder Jess Kennedy, the company increased average revenue per loan by 31% while reducing average cost per loan by 18%. These improvements continued into early 2026, suggesting that the company’s digital operating model is beginning to deliver operating leverage.

Several operational metrics also improved. Lead-to-application time fell from 1.1 days to roughly half a day, while the time required to move a loan from processing to closing fell from 22 days to 18 days. Conversion rates also improved. Lock-to-close conversions rose from 46% to 55.1%, reflecting stronger efficiency in the underwriting and closing process.

The company attributes these improvements to automation tools embedded within its digital platform, including AI agents and workflow automation designed to accelerate borrower onboarding. Beeline’s platform focuses on borrowers who are often underserved by traditional lenders. These include self-employed workers, gig-economy participants, and younger borrowers who may face difficulties qualifying through conventional underwriting models.

Through its subsidiary Beeline Loans Inc., the company offers mortgage products tailored to borrowers with nontraditional income streams as well as real-estate investors purchasing rental properties. The model reflects broader demographic shifts in housing finance. Homeownership among younger Americans remains relatively limited. According to analysis cited by the industry publication National Mortgage Professional (https://ibn.fm/FMO3W), 26.1% of Gen Z adults and 54.9% of millennials owned homes in 2024, reflecting structural barriers in mortgage access.

Beeline’s automated underwriting tools aim to address that gap by evaluating borrower data rapidly and providing a qualification decision within minutes. The company’s digital workflow also shortens closing timelines. Beeline says loans can typically close in 14 to 21 days, significantly faster than the industry average.

In addition to serving homebuyers, the company has seen growing demand from younger investors purchasing rental properties. Management says this segment has become an important driver of loan volume.

In addition to its core mortgage business, Beeline is expanding into new transaction-based revenue streams. During the fourth quarter, the company launched BeelineEquity, a platform designed to allow homeowners to access a portion of their home equity without refinancing or taking on additional debt. The product allows homeowners to sell a fractional interest in their property while retaining ownership. Initial transactions were completed and recorded on a blockchain infrastructure during the quarter.

Liuzza described the platform as a way to unlock liquidity in the housing market. “There is nearly $40 trillion of home equity in the United States that is effectively illiquid,” he said. “BeelineEquity is designed to unlock that liquidity … As the market develops, we believe Beeline is uniquely positioned as a first mover with a fully integrated platform.”

Unlike traditional mortgage products, Beeline’s platform generates revenue through transaction fees rather than interest spreads, with the company earning approximately 3.5% per transaction while providing services such as customer acquisition, property analysis, title settlement, and compliance. The company believes the structure could provide a more capital-light revenue stream compared with traditional lending.

Chief financial officer Christopher Moe said Beeline ended the year with a stronger balance sheet. The company reported full-year 2025 revenue of $7.8 million, consisting primarily of gains on loan sales, origination fees, and title services. Operating expenses totaled $27.3 million, with roughly 30% related to non-cash items such as stock-based compensation.

Importantly for investors, the company finished the year without corporate debt, aside from warehouse lines used to fund mortgage originations. Warehouse lending capacity expanded significantly during the year as well, supporting continued loan growth.

Looking ahead, management expects revenue growth to accelerate as the platform scales. Kennedy outlined three strategic priorities for 2026:

• Expanding the core mortgage business while improving loan-level efficiency.
• Scaling the BeelineEquity platform in a controlled manner.
• Expanding software-as-a-service and artificial intelligence capabilities across the platform.

Management believes these initiatives could move the company toward positive operating cash flow as transaction volumes increase.

“Our objective is straightforward,” Kennedy said during the call. “Strengthen Beeline’s financial profile while building a scalable platform capable of delivering sustainable long-term high-margin growth and providing an exceptional customer experience.”

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”).
• LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system.
• The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far.

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.

The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing therapies rather than replacing them.

In short, the compound works around a novel concept known as activation lethality, where it triggers cancer cells to be more vulnerable and susceptible to these therapies and stops their ability to repair themselves once they’ve been damaged. This makes the compound specifically useful against difficult-to-treat cancers, as these will often survive radiation and chemotherapy by repairing DNA damage, a process which LB-100 aims to help prevent.

Without solutions like LB-100, many cancers would remain resistant to common therapies, which inevitably leads to worse outcomes for patients. Also, while some direct natural PP2A inhibitors do exist, these are often too toxic to use safely in treatment.

In addition to being effective and helpful in the fight against cancer, LB-100 has also demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies.

Currently, the compound is being evaluated in numerous leading cancer research institutions, including MD Anderson Cancer Center, the Netherlands Cancer Institute, and international research groups. Ongoing trials for LB-100 include combining it with immunotherapy in metastatic MSI-low colon cancer and ovarian clear cell carcinoma, and combination therapy alongside chemotherapy in advanced soft tissue sarcoma.

These studies are being done in collaboration with leading academic cancer centers and industry partners, highlighting LIXTE’s emphasis on externally validated clinical execution.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• GPS jamming has emerged as a key modern warfare tactic, using high-powered radio signals to disrupt satellite navigation and shape both offensive operations and defensive countermeasures on the battlefield.
• This sparks major concern for many organizations and military forces, as several aspects of war rely on GPS, such as tracking, navigation, communication, and others.
• To fight back against GPS jamming, companies like SPARC AI have created GPS-free technology to deliver real-time insights, detection, and tracking, without having to rely on radar, lidar, and sensors.

In today’s rapidly evolving battlefield, drones have become one of the most influential tools in modern warfare, reshaping how militaries gather intelligence, navigate contested environments, and execute operations. Yet as drone usage expands, so does the threat of GPS jamming, a tactic that overwhelms satellite signals with high-powered radio interference, effectively blinding autonomous systems and disrupting navigation in critical moments. This challenge is pushing defense technology companies like SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) to develop next-generation solutions that allow drones to operate, navigate, and acquire targets even in GPS-denied environments, where traditional systems would fail.

In war, GPS interference is used to disrupt communications, mislead enemy navigation, ground unauthorized drones, deny precision strikes, and obscure troop or fleet movements. What once seemed like a futuristic electronic warfare tactic is now a daily reality in active conflict zones. Recent interference across the Middle East, particularly in the Strait of Hormuz, has shown how widespread GPS jamming and spoofing can create chaos, with ships appearing on land, navigation systems failing, and maritime traffic slowing dramatically due to unreliable positioning data.

GPS has become a foundational tool for modern military and commercial operations, and when interference occurs, the consequences can be severe. Aircraft and ships can lose situational awareness, vessels may struggle to avoid collisions in crowded shipping lanes, and expensive guided systems risk failure at critical moments.

In addition to jamming, GPS spoofing has also become prevalent and is even more of a problem. Instead of simply interrupting and overwhelming GPS signals like jamming does, spoofing feeds false location data to receivers, causing drones, ships, aircraft, or missiles to believe they are somewhere they are not. In heavily contested regions, this has led to ships broadcasting incorrect positions, navigation systems displaying chaotic movement patterns, and entire fleets slowing or stopping because operators can no longer determine where surrounding vessels are.

As a result, relying solely on GPS is becoming risky, especially in war zones, conflict areas, GPS-denied regions, or places with inconsistent or poor connections. However, companies like SPARC AI Inc. are combating GPS jamming and spoofing by developing GPS-free technology.

Specifically, SPARC AI develops target acquisition systems and autonomous navigation software that uses known landmark coordinates to calculate and correct your position. SPARC AI’s flagship technology, Overwatch, unifies all SPARC AI technologies, including its Target Acquisition, Mobile, and Navigation systems, into a single mission-ready platform that fuses detection, classification, tracking, and navigation in real time. The platform is hardware-agnostic and can integrate across different drone manufacturers and systems, making it scalable for both defense and rescue fleets to conduct surveillance. As more drones use the system, Overwatch strengthens through operational data, improving reliability and mission performance in GPS-denied environments such as active conflict zones.

The platform uses camera telemetry data to figure out the location of any visible object and constructs a 3D understanding of the terrain and position, using advanced mathematical modeling, to get GPS-level accuracy.

With GPS jamming likely remaining a useful tactic going forward in war, adopting a GPS-free approach may help military forces and organizations to navigate, track, and communicate successfully in risky environments.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

• In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability.
• The significance of the UK designation extends beyond a single program.
• The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease.

A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development that highlights both the potential of the therapy and the growing strength of the company’s rare disease pipeline.

In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability. Developing a new medicine is a complex and lengthy process that can take more than a decade and require significant investment, with only a small percentage of drug candidates ultimately receiving approval. Because of these challenges, savvy companies maintain a pipeline of multiple candidates at various stages of development to increase the likelihood of long-term success and to mitigate the inherent risks of drug development.

The importance of a strong pipeline is further underscored by industry data on clinical success rates. Research shows that an estimated 12% of drug candidates that enter clinical trials ultimately receive approval, highlighting the high level of attrition within the development process. This reality reinforces the need for companies to continuously advance new candidates and expand their development programs in order to sustain growth and deliver new therapies to patients.

Beyond risk management, a well-developed pipeline also allows companies to leverage scientific expertise across multiple programs and therapeutic areas. By advancing a portfolio of candidates that may share underlying technologies or mechanisms of action, companies can improve development efficiency and create opportunities for broader clinical impact. This approach is particularly important in the rare disease space, where scientific complexity and limited patient populations make each individual program both challenging and highly significant.

Soligenix’s recent progress with SGX945 reflects this broader strategic focus. According to the company, the UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to SGX945 (dusquetide) for the treatment of Behçet’s Disease, a rare inflammatory condition. This designation is awarded to therapies that demonstrate the potential to address serious conditions with unmet medical needs and represents an early step toward inclusion in the United Kingdom’s Early Access to Medicines Scheme.

The significance of this designation extends beyond a single program. By achieving recognition from a major international regulatory authority, Soligenix strengthens the credibility of its development efforts while potentially accelerating the path toward patient access. The Early Access to Medicines Scheme is designed to provide patients with life-threatening or seriously debilitating conditions earlier access to promising therapies prior to full regulatory approval, underscoring the importance of such designations in advancing both clinical development and patient care.

SGX945 is based on dusquetide, a synthetic peptide that belongs to a class of compounds known as innate defense regulators. These molecules are designed to modulate the body’s innate immune response, shifting it toward an anti-inflammatory, anti-infective and tissue-healing profile, representing a novel mechanism of action in immune-related conditions. This approach is being applied to diseases such as Behçet’s disease, a rare inflammatory disorder of the blood vessels characterized by recurring symptoms that can significantly affect quality of life. 

Clinical data referenced in the announcement highlight the therapy’s potential. In a phase 2a pilot study, SGX945 demonstrated improvement in oral ulcer outcomes among patients with Behçet’s Disease, with positive responses observed in seven of eight treated individuals. The therapy was also reported to be well tolerated, with no treatment-related adverse events observed during the study period.

The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug and fast track designations from the U.S. Food and Drug Administration for Behçet’s disease. Such designations can provide important incentives for continued development, including regulatory support and potential market exclusivity, further reinforcing the strategic value of advancing this program within Soligenix’s broader pipeline.

Soligenix continues to develop a diversified portfolio of therapeutic candidates through its specialized biotherapeutics platform. The company’s pipeline includes programs targeting rare inflammatory diseases, oncology indications such as cutaneous T-cell lymphoma and additional areas of unmet medical need. 

The recognition of SGX945 by the UK regulatory authority represents a meaningful step forward not only for the individual therapy but also for the overall strength of Soligenix’s pipeline. In an industry defined by long development timelines and some uncertainty, milestones such as this help validate scientific approaches, support continued investment and bring the possibility of new treatments closer to patients who need them most.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address.
• Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample.
• The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods.
• The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs, to expand access to its cardiovascular testing solutions.
• Recent developments include expanded provider partnerships across the United States, finalized CMS reimbursement rates of $854 for its clinical tests, initial international expansion into India, and clinical data presentations supporting its ability to detect forms of coronary heart disease that traditional tools may miss.

Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators.

At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.

Cardio Diagnostics was founded to develop and commercialize clinical tests and data solutions that enable earlier detection and more precise management of cardiovascular disease across clinical and non-clinical settings.

The company is headquartered in Chicago, Illinois.

Portfolio

The company’s portfolio brings together epigenetic and genetic insights with artificial intelligence to generate actionable information for cardiovascular care. This approach underpins a suite of blood-based tests and platforms designed for use across both individual patient care and broader population health settings.

Epi+Gen CHD(TM)

Epi+Gen CHD(TM) is a prescription-only blood test that assesses a patient’s three-year risk of a coronary heart disease (“CHD”) event, including heart attack and sudden death. The test evaluates three epigenetic and five genetic biomarkers and applies artificial intelligence to generate a personalized risk score. It is designed to assess risk regardless of the presence of traditional factors and is non-invasive, requiring no fasting or radiation. In clinical validation studies, the test has demonstrated approximately two times greater sensitivity than conventional risk calculators and enables ongoing monitoring through epigenetic biomarkers that can change in response to intervention.

PrecisionCHD(TM)

PrecisionCHD(TM) is a prescription-only blood test that aids in the detection and management of coronary heart disease by identifying molecular signals associated with the condition. The test evaluates 10 epigenetic and six genetic biomarkers and uses artificial intelligence to determine whether a disease signal is present. It provides patient-specific insights into the molecular drivers of disease, supporting more individualized care decisions, and is designed to detect both obstructive and non-obstructive forms of CHD in a non-invasive manner.

HeartRisk(TM)

HeartRisk(TM) is a population-level cardiovascular risk intelligence platform that integrates anonymized clinical, claims, industry, and geographic data to provide real-time insights into heart disease risk across defined populations. The platform enables organizations to quantify risk, project future healthcare costs, benchmark against peer groups, and track changes over time, supporting more informed planning and risk management strategies.

CardioInnovate360(TM)

CardioInnovate360(TM) is a biopharma research platform that leverages artificial intelligence and epigenetics to support the discovery, development, and validation of cardiovascular therapies. The platform is designed to identify novel biomarkers and disease pathways, optimize clinical trial design through improved patient stratification, and enable the development of scalable, non-invasive diagnostic tools.

Market Opportunity

Cardiovascular disease (“CVD”) is the leading cause of death in the United States, responsible for nearly one in three deaths. It encompasses a range of conditions, including CHD, stroke, heart failure, and peripheral artery disease, and continues to represent a significant and persistent healthcare burden.

Coronary heart disease is the most common form of CVD and often develops without symptoms, with a heart attack frequently serving as the first indication of disease. In the U.S., one in 20 adults over the age of 20 lives with CHD, and it is the second leading cause of hospitalization, adding approximately $13,000 in annual healthcare costs per patient. An additional three to four million Americans are affected by ischemia with no obstructive coronary arteries (“INOCA”), a subset of CHD.

Heart attacks occur approximately every 40 seconds in the U.S., with more than 800,000 events annually, and one in five occurring without warning. While an estimated 80–90% of cardiovascular disease is preventable through early detection and proactive management, traditional approaches can leave gaps, as approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%.

Leadership Team

Meesha Dogan, PhD, Chief Executive Officer and Co-Founder, has served as CEO and a director since inception and co-founded the company alongside Dr. Philibert. She has more than a decade of experience working at the intersection of artificial intelligence, epigenetics, and genetics, leading the development and commercialization of DNA-based cardiovascular tests. Dr. Dogan is an inventor on multiple granted and pending patents and holds a PhD in Biomedical Engineering and BSE/MS degrees in Chemical Engineering from the University of Iowa.

Robert Philibert, MD, PhD, Chief Medical Officer and Co-Founder, has served as CMO and a director since inception and co-founded the company with Dr. Dogan. He is a professor at the University of Iowa with joint appointments across psychiatry, neuroscience, molecular medicine, and biomedical engineering, and has published more than 200 peer-reviewed manuscripts. Dr. Philibert has received numerous NIH grants and holds patents related to epigenetics, including work on behavioral biomarkers.

Tim Dogan, PhD, Chief Technology Officer, has served as CTO since May 2022 after joining the company in 2019 as its first employee. He played a key role in developing the company’s Integrated Multi-Omics Engine(TM) and is a co-inventor on multiple patent-pending technologies. Dr. Dogan holds a PhD and BSE/MS degrees in Mechanical Engineering from the University of Iowa.

Elisa Luqman, JD, MBA, Chief Financial Officer, has served as CFO since March 2021 and has experience in public company finance, compliance, and corporate governance. She has held senior leadership roles at Clinigence Holdings Inc. and currently serves as Chief Legal Officer (SEC) at Nutex Health Inc., overseeing SEC reporting and compliance. Ms. Luqman holds a JD and MBA in Finance from Hofstra University.

For company information, visit the company’s website at https://cdio.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO